TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: APLLTD · data 2026-11-02
Alembic Pharmaceuticals Limited
In plain words
Price: 19.4% below its 52-week high of ₹998.
Delivery: 56.5% of traded shares were kept for delivery over the last 10 sessions, against 53.0% over the last 60.
Latest results: a net profit of ₹173 cr for the quarter ended Jun 2026 (+12.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹7,784 cr |
| Net profit (last 12 months) | ₹693 cr |
| Sales growth, 3 years (yearly) | 9.0% |
| Profit growth, 3 years (yearly) | 25.4% |
At a glance
Promoters 69.9% (+0.1 pts in a year), pledged 0.0%, institutions 20.0%.
P/E 22.8, dividend yield 1.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.3%, ROCE 11.8%, operating margin 10.6%: how much profit it earns on the money it uses.
Debt/equity 0.25, Profit growth 25.4% and sales growth 9.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 25.4% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
APLLTD Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,149.77 crore, up 25.7% YoY and up 16.3% QoQ.
Net profit was ₹173.07 crore, up 12.1% YoY and down 13.6% QoQ.
Operating margin was 15.4% (16.4% a year ago).
EPS was ₹8.8, up 12.1% YoY and down 14.6% QoQ.
APLLTD के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,149.77 करोड़; पिछले साल की तुलना में 25.7% की बढ़त, पिछली तिमाही की तुलना में 16.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹173.07 करोड़; पिछले साल की तुलना में 12.1% की बढ़त, पिछली तिमाही की तुलना में 13.6% की गिरावट।
ऑपरेटिंग मार्जिन: 15.4% (एक साल पहले 16.4%)।
EPS: ₹8.8; पिछले साल की तुलना में 12.1% की बढ़त, पिछली तिमाही की तुलना में 14.6% की गिरावट।
APLLTDના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,149.77 કરોડ; ગયા વર્ષની સરખામણીએ 25.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 16.3% વધારો.
ચોખ્ખો નફો: ₹173.07 કરોડ; ગયા વર્ષની સરખામણીએ 12.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 15.4% (એક વર્ષ પહેલાં 16.4%).
EPS: ₹8.8; ગયા વર્ષની સરખામણીએ 12.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 14.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
22/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 4/30: Delivery 56.7% over the last 20 sessions vs 51.3% in the 40 before (1.11x); shares delivered per day 0.75x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 62/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 4 Aug 26Results Q1 FY27 results: profit +12.1% YoY +1.5% next session
- 29 Jul 26Dividend Dividend ₹12 (ex-date) -2.0% next session
- 15 May 26Results Q4 FY26 results: profit +27.7% YoY -7.8% next session
- 5 Feb 26Results Q3 FY26 results: profit −3.9% YoY -0.1% next session
- 4 Nov 25Results Q2 FY26 results: profit +20.4% YoY -1.0% next session
- 5 Aug 25Results Q1 FY26 results: profit +14.6% YoY -2.0% next session
- 29 Jul 25Dividend Dividend ₹11 (ex-date) +0.7% next session
- 12 May 25Results Q4 FY25 results: profit −12.0% YoY -0.6% next session
- 3 Feb 25Results Q3 FY25 results: profit −23.3% YoY -6.6% next session
- 7 Nov 24Results Q2 FY25 results: profit +12.3% YoY -8.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹2,150 cr | ₹173 cr | +12.1% | 15.4% | 8.8 |
| Mar 2026 | ₹1,848 cr | ₹200 cr | +27.7% | 12.3% | 10.31 |
| Dec 2025 | ₹1,876 cr | ₹133 cr | -3.9% | 15.6% | 6.76 |
| Sept 2025 | ₹1,910 cr | ₹185 cr | +20.4% | 16.5% | 9.4 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 69.87% | 69.87% | 69.74% | 69.74% |
| Foreign institutions (FII) | 4.55% | 4.18% | 4.25% | 4.24% |
| Domestic institutions (DII) | 15.43% | 15.94% | 16.18% | 16.17% |
| Mutual funds | 8.50% | 8.73% | 8.18% | 8.22% |
| Retail investors | 6.48% | 6.52% | 6.34% | 6.35% |
| Number of shareholders | 86,532 | 86,796 | 86,432 | 87,000 |
Common questions
What was Alembic Pharmaceuticals Limited's latest quarterly profit?
Alembic Pharmaceuticals Limited reported a net profit of ₹173 cr for the quarter ended Jun 2026 (+12.1% on the same quarter a year earlier), on revenue of ₹2,150 cr.
How much do promoters hold in Alembic Pharmaceuticals Limited?
Promoters held 69.87% of Alembic Pharmaceuticals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Alembic Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.25.
What is Alembic Pharmaceuticals Limited's P/E ratio?
About 22.8, based on the last 12 months' earnings and a price of ₹804.6 (data 2026-11-02).
What is the 52-week high and low of Alembic Pharmaceuticals Limited?
The 52-week high is ₹998 and the 52-week low is ₹635.8.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals Limited | ₹804.6 | ₹15,682 cr | 22.8 | — | 12.3% | 11.8% | 0.25 | -10.6% |
| PFIZER LIMITED | ₹3,630.6 | ₹16,867 cr | 22.6 | — | 17.2% | 20% | 0.02 | -31.8% |
| Eris Lifesciences Ltd | ₹1,184.4 | ₹16,088 cr | 23.1 | 4 | 18.3% | 15.6% | 0.6 | -27.2% |
| AstraZeneca Pharma India Limited | ₹6,439 | ₹15,918 cr | 94.9 | — | 23.9% | 25.5% | 0.13 | -32.0% |
| NATCO Pharma Limited | ₹784.7 | ₹15,350 cr | 12.4 | — | 16.9% | 15.6% | 0.08 | -5.1% |
| Jubilant Pharmova Limited | ₹924 | ₹14,729 cr | 41.7 | — | 6% | 6.5% | 0.51 | -17.1% |
Compare APLLTD with PFIZER in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open APLLTD in TickerKhoj →